000119707 001__ 119707
000119707 005__ 20240228134951.0
000119707 0247_ $$2doi$$a10.1016/j.acra.2014.04.011
000119707 0247_ $$2pmid$$apmid:24998693
000119707 0247_ $$2ISSN$$a1076-6332
000119707 0247_ $$2ISSN$$a1878-4046
000119707 037__ $$aDKFZ-2017-00334
000119707 041__ $$aeng
000119707 082__ $$a610
000119707 1001_ $$0P:(DE-HGF)0$$aBretschi, Maren$$b0$$eFirst author
000119707 245__ $$aAssessing treatment response of osteolytic lesions by manual volumetry, automatic segmentation, and RECIST in experimental bone metastases.
000119707 260__ $$aPhiladelphia, PA [u.a.]$$bElsevier$$c2014
000119707 3367_ $$2DRIVER$$aarticle
000119707 3367_ $$2DataCite$$aOutput Types/Journal article
000119707 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1488877432_30484
000119707 3367_ $$2BibTeX$$aARTICLE
000119707 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119707 3367_ $$00$$2EndNote$$aJournal Article
000119707 520__ $$aAim of the study was to compare between volumetric and unidimensional approaches for treatment response monitoring in a nude rat model of experimental bone metastases. For the volumetric approach, an automated segmentation algorithm of osteolytic lesions was introduced and compared to manual volumetry.Nude rats bearing osteolytic metastases were treated with zoledronate and sunitinib and compared to controls. Treatment response was assessed longitudinally in vivo using flat-panel volumetric computed tomography at days 30, 35, 45, and 55 after tumor cell inoculation. The mean sizes and volumes of osteolytic lesions were determined according to response evaluation criteria in solid tumors (RECIST) and by automated and manual volumetry (software: MITK [The Medical Imaging Interaction Toolkit, Heidelberg, Germany] and VIRTUOS, Heidelberg, Germany).In contrary to RECIST, the manual volumetric approach indicated a significant decrease in osteolytic lesion volume in response to treatment. The presented automatic segmentation algorithm for treatment monitoring identified bone metastases adequately and assessed changes in the osteolytic lesion volume over time according to manual volumetry.In an animal model, volumetric treatment response assessment of osteolytic bone metastases is superior to unidimensional measurements, and automated volumetric segmentation may be a valuable alternative to manual volume determination.
000119707 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000119707 588__ $$aDataset connected to CrossRef, PubMed,
000119707 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000119707 650_7 $$2NLM Chemicals$$aBone Density Conservation Agents
000119707 650_7 $$2NLM Chemicals$$aDiphosphonates
000119707 650_7 $$2NLM Chemicals$$aImidazoles
000119707 650_7 $$2NLM Chemicals$$aIndoles
000119707 650_7 $$2NLM Chemicals$$aPyrroles
000119707 650_7 $$06XC1PAD3KF$$2NLM Chemicals$$azoledronic acid
000119707 650_7 $$0V99T50803M$$2NLM Chemicals$$asunitinib
000119707 7001_ $$0P:(DE-He78)b51b8af8fb3459cf38fa735dc4f54e52$$aFränzle, Andrea$$b1$$udkfz
000119707 7001_ $$0P:(DE-HGF)0$$aMerz, Maximilian$$b2
000119707 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b3$$udkfz
000119707 7001_ $$0P:(DE-He78)8354679bf4f1b32938e4abbac66bbd9b$$aSemmler, Wolfhard$$b4$$udkfz
000119707 7001_ $$0P:(DE-He78)4e7bb332499544552cf19660bec6f04f$$aBendl, Rolf$$b5$$udkfz
000119707 7001_ $$0P:(DE-HGF)0$$aBäuerle, Tobias$$b6$$eLast author
000119707 773__ $$0PERI:(DE-600)2050425-1$$a10.1016/j.acra.2014.04.011$$gVol. 21, no. 9, p. 1177 - 1184$$n9$$p1177 - 1184$$tAcademic radiology$$v21$$x1076-6332$$y2014
000119707 909CO $$ooai:inrepo02.dkfz.de:119707$$pVDB
000119707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b51b8af8fb3459cf38fa735dc4f54e52$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000119707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8354679bf4f1b32938e4abbac66bbd9b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000119707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4e7bb332499544552cf19660bec6f04f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000119707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000119707 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000119707 9141_ $$y2014
000119707 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119707 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACAD RADIOL : 2015
000119707 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119707 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119707 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119707 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119707 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000119707 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000119707 9201_ $$0I:(DE-He78)E020-20160331$$kE020$$lMedizinische Physik in der Radiologie$$x0
000119707 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lMedizinische Physik in der Strahlentherapie$$x1
000119707 9201_ $$0I:(DE-He78)E013-20160331$$kE013$$lHämatoonkologische Bildgebung$$x2
000119707 980__ $$ajournal
000119707 980__ $$aVDB
000119707 980__ $$aI:(DE-He78)E020-20160331
000119707 980__ $$aI:(DE-He78)E040-20160331
000119707 980__ $$aI:(DE-He78)E013-20160331
000119707 980__ $$aUNRESTRICTED